ArticleEULAR rheumatology open2026
Maintained improvement in patient-reported outcomes in early axial spondyloarthritis following certolizumab pegol dose reduction: findings from the randomised period of a phase 3b trial.
Article in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02505542 (A Multicenter, Open-label), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the phase 3b C-OPTIMISE study (ClinicalTrials.gov, NCT02505542), approximately 80% of patients with early active axial spondyloarthritis (axSpA) remained flare-free from week (W)48 to W96 with full-dose and reduced-dose certolizumab pegol (CZP) after gaining sustained remission (Axial Spondyloarthritis Disease Activity Score <1.3 at W32/36, and W48; if <1.3 at W32, <2.1 was required at W36, or vice versa). Patient-reported outcomes (PROs) are presented throughout the maintenance period for patients in sustained remission at W48. Methods: After open-label CZP through W48, patients were double-blind randomised 1:1:1 to full-dose CZP (200 mg every 2 weeks [Q2W]), reduced-dose CZP (Q4W), or placebo. Prespecified PROs: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI). Results: At W48, 43.9% of patients (323/736) achieved sustained remission. At timepoints from W48 through W96, PRO scores were maintained with full-dose and reduced-dose CZP, vs rapid increases (worsening) with placebo. At W96, least squares mean score change from W48 with full-dose and reduced-dose CZP vs placebo ( Conclusions: In patients who achieved remission at W48, reduced-dose and full-dose CZP maintained axSpA in remission without impacting PROs through W96.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.